Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
September 23, 2024 06:30 ET
|
XOMA Corporation
MIPLYFFA(TM) becomes 6th commercial asset in XOMA Royalty's portfolio
Orphazyme announces US Early Access Program for Niemann-Pick disease Type C
January 06, 2020 08:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....